BrainLAB, a developer of image-guided surgery (IGS) and stereotactic radiosurgery systems, has prevailed in its patent battle with Nomos. BrainLAB announced Feb. 9 that the U.S. Court of Appeals for the Federal Circuit in Washington, DC, has upheld a
BrainLAB, a developer of image-guided surgery (IGS) and stereotactic radiosurgery systems, has prevailed in its patent battle with Nomos. BrainLAB announced Feb. 9 that the U.S. Court of Appeals for the Federal Circuit in Washington, DC, has upheld a lower court ruling that BrainLAB's ExacTrac product does not infringe U.S. patent 5,411,026 for Nomos' BAT ultrasound-based target locating device. ExacTrac is BrainLAB's patient positioning system for the treatment of tumors with stereotactic radiotherapy/radiosurgery. The system's ultrasound localization allows a daily verification of the position of organs, such as the prostate or liver, which improves the precision of radiotherapy by allowing adjustments for shifts in organ position.
New Study Assesses Long-Term Outcomes of PSMA PET Use in PCa Recurrence Cases
October 24th 2024For patients with biochemical recurrence of prostate cancer, PSMA PET imaging may facilitate a 12.8 percent lower incidence of prostate cancer mortality in contrast to the combination of CT and bone scan, according to long-term outcome estimates from a new decision-analytic modeling study.
Can Diffusion MRI Predict Patient Response to Neoadjuvant Chemotherapy for Breast Cancer?
October 23rd 2024A model emphasizing time-dependent diffusion MRI was 15 percent more effective than apparent diffusion coefficient (ADC) measurements at predicting pathologic complete response to neoadjuvant chemotherapy for women with breast cancer, according to new research.